Avacincaptad Pegol for Geographic Atrophy
How Avacincaptad Pegol Treats Geographic Atrophy
Geographic atrophy (GA) is the late stage of dry age-related macular degeneration. Patches of retinal pigment epithelium and photoreceptor cells die and expand over time, creating blind spots in your central vision. You may notice difficulty reading, trouble seeing faces, or gaps in your visual field that grow larger over months and years.
Unlike wet AMD, geographic atrophy involves no leaking blood vessels. The damage comes from immune-mediated cell death in the macula, the part of your retina responsible for sharp, detailed vision. GA affects both eyes in most patients, though one eye may be more advanced than the other.
Avacincaptad pegol is a complement C5 inhibitor. In geographic atrophy, a part of your immune system called the complement cascade becomes overactive and destroys healthy retinal cells. Avacincaptad pegol is an RNA aptamer that blocks complement factor C5, preventing it from splitting into pro-inflammatory fragments C5a and C5b that trigger inflammation and cell death. According to the AAO (2023), this targets a point downstream in the cascade compared to C3 inhibitors.
According to the AAO (2023), the FDA approved avacincaptad pegol in August 2023 for geographic atrophy secondary to AMD. This made it the second complement inhibitor approved for GA, giving patients and their doctors another treatment option.
The GATHER1 trial showed avacincaptad pegol reduced GA lesion growth rate by 35 percent compared to a sham control, according to published data (PMC, 2024). The AAO (2023) also reported a 14 percent reduction in lesion growth over one year in the GATHER2 trial. Both trials measured the size of GA lesions using advanced imaging over 12 months of treatment.
Like other GA treatments, avacincaptad pegol does not restore lost vision. It preserves the vision you still have by slowing the rate of retinal cell loss. The benefit builds over time, with treated eyes showing less atrophy growth compared to untreated eyes.
Your retina specialist may recommend avacincaptad pegol if you have geographic atrophy from dry AMD. This medication works for GA lesions at different stages, though starting treatment while you still have usable central vision gives you the most to preserve. According to the AAO (2023), avacincaptad pegol carries an increased risk of wet AMD conversion compared to no treatment, so your doctor will factor in your overall eye health before prescribing it. Active eye infections or known allergy to the drug are contraindications.
What Treatment Looks Like
Your retina specialist delivers avacincaptad pegol as an intravitreal injection. Before the procedure, your doctor applies numbing drops and antiseptic to your eye. A small lid holder keeps your eye open. The doctor inserts a small needle through the white part of your eye and injects the medication into the gel-filled vitreous cavity. The injection takes seconds. Most patients report feeling pressure rather than pain.
According to FDA prescribing information (2023), each dose delivers 2 mg of avacincaptad pegol. Your vision may be blurry for a few hours after the procedure, but you can return to most activities the same day.
According to FDA prescribing information (2023), avacincaptad pegol is given as an intravitreal injection every 28 days, or about once a month. Your retina specialist administers every injection in the office. Treatment is ongoing because GA progression resumes if you stop the medication. Maintaining a consistent monthly schedule gives you the best chance of slowing lesion growth over time.
According to a clinical review (Drugs.com, 2024), your doctor checks your eye pressure before and after each injection appointment. A temporary rise in intraocular pressure (IOP) can occur after any intravitreal injection. If pressure stays elevated, your doctor may prescribe drops or adjust your treatment plan. Your retina specialist also examines your retina at each visit for any signs of wet AMD conversion or other changes.
Bring a driver to your injection appointment since your vision may be blurry after the procedure. Wear comfortable clothing with a loose collar, as you will be sitting in an exam chair. Let your doctor know about any changes in your vision or health since your last visit. Your appointment will include a vision check, imaging, the injection, and a post-injection pressure check.
Risks and Monitoring
According to the AAO (2023), common side effects include inflammation inside the eye, bleeding on the white of the eye (subconjunctival hemorrhage), blurred vision, and temporary elevation of eye pressure. These effects are mild and resolve within days. Your retina specialist monitors for them at each visit and can manage them if they persist.
- Eye redness or irritation for one to two days
- Mild discomfort or gritty feeling
- Small floaters that clear within a week
- Temporary sensitivity to light
According to the AAO (2023), avacincaptad pegol carries an increased risk of developing wet AMD (neovascularization) compared to no treatment. Your retina specialist will check for signs of abnormal blood vessel growth at every appointment using OCT imaging and a dilated exam. If wet AMD develops, anti-VEGF injections can treat it. Catching conversion early leads to better visual outcomes, which is one reason your monthly follow-up visits matter.
Call your retina specialist the same day if you notice sudden vision loss, a sharp increase in floaters or flashes of light, growing eye pain, or a dark curtain across part of your vision. These symptoms may indicate a serious complication such as endophthalmitis (an eye infection) or retinal detachment that needs urgent treatment. Do not wait for your next scheduled appointment if you develop any of these warning signs.
Common Questions About Avacincaptad Pegol for GA
Avacincaptad pegol and pegcetacoplan both target the complement cascade but at different points. Avacincaptad pegol blocks C5 (downstream), while pegcetacoplan blocks C3 (upstream). According to the AAO (2024), avacincaptad pegol may have fewer adverse events based on comparative data. Your retina specialist will recommend the option that best fits your medical profile and treatment goals.
The FDA-approved dosing for avacincaptad pegol is monthly (every 28 days). Unlike pegcetacoplan, which offers both monthly and every-other-month options, avacincaptad pegol has one approved schedule. Your retina specialist may discuss future options as ongoing research explores alternative dosing intervals.
You will not feel the medication working or see improvement in your vision. Your doctor measures the benefit through imaging that tracks the size of your GA lesions over time. Slowing lesion growth means your remaining vision stays intact longer than it would without treatment. Most clinical trial results showed measurable differences after six to twelve months of treatment.
Your retina specialist will decide based on the GA status of each eye and your overall risk factors. Treating both eyes is possible, but your doctor will weigh the wet AMD conversion risk for each eye before recommending bilateral treatment. If your doctor treats both eyes, you may receive injections on the same day or at separate visits depending on their approach.
Talk to your retina specialist about scheduling challenges. Missing doses reduces the treatment benefit, so consistent monthly visits matter. Some practices offer flexible scheduling, appointment reminders, or can coordinate your GA injection with other eye care visits to reduce trips.
Coverage varies by insurance plan. Medicare Part B covers physician-administered intravitreal injections when your doctor certifies medical necessity. Some commercial and Medicare Advantage plans may require prior authorization before starting treatment. Your retina specialist can help verify your coverage and connect you with manufacturer assistance programs if needed.
Take the Next Step
If you have geographic atrophy, ask your retina specialist whether avacincaptad pegol could help slow the progression of your condition. Starting treatment while you still have functional central vision gives you the best opportunity to maintain your independence and daily activities.